Physician profile
Muhammad A Awan
NPI 1518043108
$5,695.07
in general payments reported to CMS, 2019-2025
52 companies · $939 in 2025
The $939 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $878 · 2020: $455 · 2021: $1,178 · 2022: $1,013 · 2023: $613 · 2024: $619 · 2025: $939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,171.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $994.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Ibsa Pharma INC. | $444.04 | 2021-2025 | Tirosint, Licart, Tirosint |
| Abbvie INC. | $400.72 | 2021-2025 | Ubrelvy |
| Novartis Pharmaceuticals Corporation | $375.69 | 2019-2023 | |
| Astellas Pharma US INC | $351.66 | 2019-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $312.48 | 2019-2024 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.23 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $258.24 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $243.11 | 2019-2024 | Zepbound, Jardiance, Mounjaro |
| Insulet Corporation | $185.71 | 2024-2025 | Omnipod |
| Pfizer INC. | $163.10 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $153.67 | 2019-2022 | |
| Esperion Therapeutics, INC. | $147.77 | 2021-2023 | Nexletol |
| Amgen INC. | $128.46 | 2019-2025 | Otezla, Repatha, Repatha |
| Xeris Pharmaceuticals, INC. | $122.53 | 2021-2023 | Gvoke Hypopen |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Awan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.